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osting by EAbstract An enantioselective stability-indicating high performance liquid chromatographic
method was developed for the analysis of arotinolol in standard solution. The degradation behav-
iour of arotinolol was investigated under different stress conditions recommended by International
Conference on Harmonization (ICH). Resolution of the drug and complete separation from its deg-
radation products were successfully achieved on a Chirobiotic V column, using UV detector set at
315 nm, polar organic mobile phase (POM) consisting of methanol:glacial acetic acid:triethylamine,
100:0.02:0.03, (v/v/v), and a ﬂow rate of 1 ml/min. The drug was subjected to oxidation, hydrolysis,
photolysis, and heat to apply stress conditions. The drug was found to degrade in alkaline, acidic,
oxidative conditions and when exposed to heat. The drug was stable to sunlight. The method
reported here has also been successfully applied to pharmaceutical formulation and to human
plasma that spiked with stock solutions of arotinolol enantiomers.
Arotinolol enaniomers were recovered from plasma by using liquid–liquid extraction procedure
with ethyl ether. The method was highly speciﬁc, where degradation products and coformulated
compounds did not interfere, and was sensitive with good precision and accuracy and was linear
over the range of 50–400 ng/ml (R2 > 0.9981) with a detection limit of 20 ng/ml for each enantio-
mer. The mean extraction efﬁciency for arotinolol was in the ranges 96–104% for each enantiomer.
The mean relative standard deviation (RSD) of the results of within-day precision and accuracy of
the drug were 67.1%. There was no signiﬁcant difference between inter- and intra-day studies for
each enantiomers which conﬁrmed the reproducibility of the assay. The overall recoveries of aroti-
nolol enantiomers from pharmaceutical formulations were in the ranges 97.6–101.8%.
ª 2010 King Saud University. All rights reserved.m (M.A. Sultan).
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lsevier1. Introduction
The stability-indicating assay is a method applied to ensure
the stability of a drug. The presence of impurities and degra-
dation products can change chemical, pharmacological and
toxicological properties of drugs having signiﬁcant impact
on their quality and safety. Since drugs are, especially, sensi-
tive to environmental factors, strict storage conditions are
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Figure 1 Chemical structures of (A) S-(+)-arotinolol, (B) R-
()-arotinolol, and (C) haloperidol (IS).
148 M.A. Sultan et al.necessary (Ahuja, 1998; Ahuja and Alsante, 2003; FDA,
1998).
The ICH guideline Q1A on Stability Testing of New Drug
Substances suggests that the testing of those features which are
susceptible to change during storage and are likely to inﬂuence
quality, safety and efﬁcacy must be done by validated stability-
indicating methods. Stress testing should be carried out on a
drug to establish its inherent stability characteristics and to
support the suitability of the proposed analytical method. It
is also suggested that stress testing should include the effect
of temperature, susceptibility across a wide range of pH values,
as well as oxidative and photolytic conditions (ICH, 2003).
Like stability-indicating study, the enantioseparation has a
great impact on the pharmacological and toxicological proper-
ties of chiral drugs in terms of the control of individual vari-
ability in clinical responses between the enantiomers. A
prerequisite for progress in acquiring knowledge of stereospe-
ciﬁc pharmacodynamics and pharmacokinetics of optical iso-
mers is the development of an enantioselective analytical
methodology. High performance liquid chromatography
(HPLC) is one of the famous analytical techniques commonly
employed in conducting stability studies (Daraghmeh et al.,
2001; Baaske et al., 1996) and in chiral separation (Pettersson
and Persson, 1998; To¨ro¨k et al., 2005). HPLC has gained pop-
ularity due to its high resolution capacity, speed, sensitivity
and speciﬁcity.
Separation of enantiomers by HPLC can be achieved using
either chiral stationary phases or chiral additives to the mobile
phase. The most common HPLC approach for resolving enan-
tiomers involves the use of chiral stationary phases (CSPs)
(Subramanian, 1994). The macrocyclic antibiotic CSPs become
a very important tool for separation of a wide range of struc-
turally different chiral compounds (Duret et al., 2000). The
most useful and popular among them, are based on teicoplanin
and vancomycin chiral selectors (Chirobiotic Handbook,
2004). The enantioselectivity of these chiral selectors are due
to several reasons: (i) they are amphoteric (i.e. contain acidic
and basic ionizable groups); (ii) they have the necessary geom-
etry and functionalities that accentuate chiral recognition in
solution; and (iii) they contain both hydrophilic and hydro-
phobic moieties (Ekborg-Ott et al., 1998).
A simpliﬁed approach has proven very effective for the res-
olution of a broad spectrum of racemate analytes. The ﬁrst
consideration in this direction is the structure of the analytes.
If the compound has more than one functional group capable
of interacting with the stationary phase and at least one of
those groups is on or near the stereogenic center, then the ﬁrst
mobile phase choice would be the polar organic phase. Due to
the strong polar groups present in the macrocyclic peptides, it
was possible to convert the original mobile phase concept to
100% methanol with an acid/base added to effect selectivity.
The key factor in obtaining complete resolution is still the ratio
of acid to base (Aboul-Enein and Ali, 2002).
Arotinolol,5-[2-(3-t-butylamino-2-hydroxypropylthio)thia-
zol-4-yl] thiophene-2-carboxamide, Fig. 1 is a b-bloking agent.
In addition it has week a-bloking activity. It is used in thera-
peutics for its antihypertensive, antiangorous and antiarrhyth-
mic properties (Imai et al., 1995). Although it is reported that
the S-(+)-enantiomer is more active than the R-()-enantio-
mer, it is clinically administered as racemic mixture (Van-Zwie-
ten, 1993). Several methods have been published for the chiral
assay of arotinolol (Moulin et al., 1992; Hefnawy, 2002;Aboul-Enein and Hefnawy, 2003). However, a stability-indi-
cating method for the assay of this drug is not available in
the literature.
The aim of this study is to establish a validated stability-
indicating HPLC method for the assay of S-(+)- and R-()-
arotinolol in standard solution and apply this method to hu-
man plasma and a pharmaceutical formulation successfully
using vancomycin CSP column as the chiral selector. None
of the reported analytical methods described stability-indicat-
ing method for the chiral determination of arotinolol in pres-
ence of its degradation products. To our knowledge, this is
the ﬁrst report of stability-indicating method for the chiral
determination of arotinolol.
2. Experimental
2.1. Chemicals and reagent
S-(+)- and R-()-arotinolol were gifts from Sumitomo Phar-
maceutical Co. (Osaka, Japan), and haloperidol was obtained
from Sigma Chemical Co. (St. Louis, MO, USA). HPLC-grade
methanol, analytical grade triethylamine, glacial acetic acid
and ethyl ether were purchased from BDH Chemicals (Poole,
UK). Analytical grade ammonium acetate, hydrochloric acid,
sodium hydroxide and hydrogen peroxide were purchased
from WINLAB (UK). Deionized water was puriﬁed using a
cartridge system (Picotech water system, RTP, NC, USA). Hu-
man plasma was obtained from King Khalid University hospi-
tal (Riyadh, KSA), and was kept frozen until use.
2.2. HPLC system
The HPLC instrument (Jasco, Japan) is equipped with a pump
(model PU-980), a UV/vis detector (model UV-975) and injec-
tion valve with 20 lL sample loop. Signal acquisition and data
handling were performed with LG computer connected to the
instrument. The CSP used in this study was the macrolide-type
antibiotic vancomycin, known as Chirobiotic V (150 · 4.6 mm
i.d.) purchased from Advanced Separation Technologies
(Whippany, NJ, USA). The mobile phase was methanol:glacial
Table 1 Validation parameters for the determination of
arotinolol enantiomers in standard solution using the proposed
method.
Parameter S-(+)-arotinolol R-()-arotinolol
Concentration range (ng/ml) 20–400 20–400
Intercept (a) 0.0640 0.0740
Slope (b) 0.0048 0.0049
Correlation coeﬃcient (r) 0.9991 0.9996
Sy/x 0.0433 0.0194
Sa 0.0275 0.0124
Sb 0.0001 0.0001
LLQ (ng/ml)a 20 20
LLD (ng/ml)b 5 5
a S/N= 10.
b S/N= 3.
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phase was ﬁltered through a Millipore membrane ﬁlter
(0.2 lm) from Nihon, Millipore (Yonezawa, Japan) and de-
gassed before use. The ﬂow rate was 1 ml/min and the detec-
tion wavelength (UV) was set at 315 nm.
2.3. Preparation of stock and standard solution
Stock solutions of individual S-(+)- and R-()-arotinolol
hydrochloridewereprepared inmethanol to givea concentration
of 80 lg/ml. The internal standard haloperidol was prepared in
methanol to give a concentration of 1 mg/ml. Appropriate dilu-
tions of the individual stock solutions of arotinolol were made
and used for constructing the calibration curves, for conducting
the stability study and for spiking the plasma.
2.4. Degradation studies
All degradation studies were performed at a drug concentra-
tion of 200 ng/ml in methanol. Acid hydrolysis was per-
formed in 0.1 and 1 M HCl at room temperature and
samples were withdrawn at different time intervals. The study
in alkaline condition was carried out in 0.01, 0.1 and 1 M
NaOH at room temperature and samples were withdrawn
at different time intervals. Oxidative study was carried out
at room temperature in 3%, 10%, 20% and 30% hydrogen
peroxide and samples were also withdrawn at different time
intervals. Photo-degradation study was performed in metha-
nol. The solution was exposed to sunlight for 3 days. Suitable
control was kept under the dark. Additionally, thermal deg-
radation was induced by storing the drug at 80 C for a per-
iod of 7 days. Samples were withdrawn at appropriate time
and subjected to HPLC analysis.
2.5. Preparation of plasma samples
Human plasma sample (0.5 ml) was placed into individual
1.5 ml Eppendrof tube and accurately measured aliquots of
S-(+)- and R-()-arotinolol were added. Then 25 ll of the
internal standard solution was added to each tube and diluted
with water to 1 ml and mixed well to give ﬁnal concentrations
of 80, 150 and 300 ng/ml of each arotinolol enantiomers. The
mixture was treated with 100 ll of 3 M ammonium acetate (pH
9) and sonicated for 5 min. The aqueous phase was extracted
with 3 · 1 ml ethyl ether. The organic phase was evaporated
to dryness. The residue was dissolved in 200 ll methanol and
injected into an HPLC system. Blank human plasma samples
were processed in the same manner using deionized water in-
stead of arotinolol enantiomers.
2.6. Preparation of tablet solutions
Ten prepared tablets were grounded and powdered. An accu-
rately weighed portion equivalent to 10 mg arotinolol was
transferred to 100 ml volumetric ﬂask diluted to the mark with
methanol. The solution was sonicated for 15 min, centrifuged
at 3000 rpm for 10 min. Accurately measured aliquots of the
supernatant were transferred to 5 ml volumetric ﬂasks contain-
ing 100 ll of the internal standard and diluted to 5 ml with
methanol to give ﬁnal concentration of 100, 220 and 340 ng/
ml of arotinolol.2.7. Recovery
The absolute recoveries of each enantiomer from plasma were
calculated by comparing drug peak area of the spiked analyte
samples to unextracted analyte of stock solution that has been
injected directly into an HPLC system. The assay absolute
recovery for each compound, at each concentration, was com-
puted using the following equation:
absolute recovery
¼ ðpeak area of extract=mean peak area of direct injectionÞ
 100:2.8. Validation of the method
2.8.1. Linearity
Under the optimized experimental conditions, the calibration
plots for the S-()- and R-(+)-arotinolol standard solution
were prepared, the statistical evaluation of the regression
parameters are shown in Table 1.
Calibration plots for the S-()- and R-(+)-arotinolol in
plasma were prepared by diluting stock solutions with pooled
human plasma to yield seven concentrations over the range of
50–400 ng/ml for each enantiomer, respectively.
Calibration standards at each concentration were extracted
and analyzed in triplicate. Calibration curves of arotinolol
enantiomers were constructed using the observed analyte peak
area over internal standard peak area versus nominal concen-
trations of the analytes. Least squares linear regression analy-
sis of the data gave slope, intercept and correlation coefﬁcient
data. From this data, a ﬁrst order polynomial model was
selected for each analyte.
2.8.2. Precision and accuracy
The within-run and between-run accuracy and precision of the
assays in plasma were determined by assaying three QC sam-
ples in triplicate over a period of 3 days. The concentrations
represented the entire range of the calibration curves. Calibra-
tion curves were prepared and analyzed daily and linear mod-
els were used to determine concentrations in the QC samples.
The nine measured concentrations per concentration level
(triplicates from three runs) were subjected to estimate the
Table 2 Chromatographic parameter data for arotinolol
enantiomers and internal standard.
Analyte Rs
a ab Kc TR (min)
c
S-(+)-arotinolol 1.20 1.15 3.87 ± 0.04 9.12 ± 0.01
R-()-arotinolo 1.76 1.23 4.50 ± 0.07 10.26 ± 0.02
Haloperidol d d 5.52 ± 0.04 12.14 ± 0.05
a Rs = (t2  t1)/0.5(w2 + w1).
b Separation factor, calculated as k2/k1.
c Mean ± SD, n= 4.
d Not calculated.
Figure 2 Chromatogram of freshly prepared arotinolol sample
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as % relative standard deviation (%RSD) = (S.D./mean) ·
100. Percent accuracy was determined (using the data from
the precision assessment) as the closeness of spiked samples
to the nominal value of in-house standards. Percent accu-
racy was reported as %error = ((nominal concentration –
measured concentration)/nominal concentration) · 100.
2.8.3. Limit of detection and limit of quantitation
The limit of detection (LOD) and the limit of quantitation
(LOQ) were determined as 3 and 10 times the baseline noise,
respectively, following The United States Pharmacopeia
(2000). The results of the statistical analysis of the experimen-
tal data, such as the slopes, the intercepts, the correlation coef-
ﬁcients obtained by the linear squares treatment of the results
along with standard deviation of the slope (Sb) and intercept
(Sa) on the ordinate and the standard deviation of the residuals
(Sy/x).
2.8.4. Selectivity
The selectivity of the assay was checked by analyzing indepen-
dent blank human plasma samples and placebo tablets sam-
ples. The chromatograms of these samples were compared
with chromatograms obtained by analyzing human plasma
samples spiked with the analytes and chromatograms obtained
by analyzing prepared tablets containing the drug, respec-
tively. Moreover, the selectivity of the assay was checked by
analyzing the stability study samples. The chromatograms of
standard arotinolol solutions were compared with chromato-
grams obtained by analyzing the stability study samples.using Chirobiotic V column (mobile phase: methanol:glacial acetic
acid:triethylamine (100:0.020:0.030, v/v/v), ﬂow rate: 1 ml/min,
UV detection: 315 nm).3. Result and discussion
3.1. Optimization of the chromatographic condition
The complex structures of macrocyclic antibiotics are
responsible for their chiral selectivity in different modes
(Aboul-Enein and Ali, 2002). The possible interactions in-
volved are p–p complexation, hydrogen bonding, inclusion
complexation, dipole interactions, steric interactions, anionic
and cationic bindings (Aboul-Enein and Ali, 2000). These
interactions take place individually or in combination, which
can result in the very high chiral recognition capacities for
these antibiotics.
The chemical structures of S-(+) – (I) and R-() – (II) aro-
tinolol and haloperidol (III) are shown in Fig. 1.
The polar organic mode (POM) which has been described
to obtain enantioselective separation with macrocyclic antibi-
otic-based CSPs (Fried et al., 1998) is a good choice for enan-
tioseparation of arotinolol. Easy-to-prepare mobile phases
composed of methanol with small amounts of acetic acid
(HAc) and triethylamine (TEA) were used. The baseline sepa-
ration of arotinolol was achieved on the vancomycin CSP col-
umn with a polar organic mobile phase consisting of
methanol:glacial acetic acid:triethylamine (100:0.02:0.03, v/v/
v) (Table 2) and Fig. 2.
When using pure methanol as mobile phase, arotinolol did
not eluted. A small addition of HAc and TEA was sufﬁcient to
elute the enantiomers in an acceptable time. An increase in the
acid and base concentrations decreases the enantioresolution
values.3.2. Degradation studies
HPLC studies of samples obtained on stress testing of arotino-
lol under different conditions suggested the following degrada-
tion behaviour.
3.2.1. Acid degradation study
The drug was stable in 0.1 M HCl at room temperature for a
period of 7 days. In 1 M HCl, 20.90% of arotinolol was hydro-
lyzed in the same period (Fig 3).
3.2.2. Alkali degradation study
It was observed that the whole drug was degraded in 1 N
NaOH at room temperature after 48 h. After 7 days no degra-
dation was observed in 0.01 N NaOH and 69.11% of the drug
was degraded in 0.1 N NaOH.
3.2.3. Oxidation study
The drug was found to be highly labile to oxidation by H2O2 at
room temperature. The reaction in 30% H2O2 resulted in com-
plete degradation of the drug in 24 h. Subsequently, study was
performed in 3%, 10% and 20% H2O2. The whole drug was
degraded after 4, 3 and 2 days, respectively.
3.2.4. Temperature study
After the drug has been exposed to 80 C for 7 days, 35.47% of
it was degraded.
Figure 3 Chromatogram of arotinolol in 1 M HCl after a period
of 7 days using Chirobiotic V column (mobile phase: metha-
nol:glacial acetic acid:triethylamine (100:0.020:0.030, v/v/v), ﬂow
rate: 1 ml/min, UV detection: 315 nm).
Table 3 Validation parameters for the determination of
arotinolol enantiomers in human plasma using the proposed
method.
Parameters S-(+)-arotinolol R-()-arotinolol
Concentration range (ng/ml) 50–400 50–400
Intercept (a) 0.04003 0.06567
Slope (b) 0.00159 0.00180
Correlation 0.9988 0.9971
Coeﬃcient (r)
Sy/x 0.01487 0.02505
Sb 0.00005 0.00009
LOQ (ng/ml) 50 50
LOD (ng/ml)a 20 20
a S/N= 3.
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No degradation was observed of drug solution in methanol
after exposure to sunlight for 3 days, indicating that light
had no effect on the degradation of arotinolol solution in
methanol.
The degradation products did not interfere with the drug
indicating that the method is highly selective, and could not
be detected in a run time of 1 h in all the degraded samples.
3.3. Applications to spiked human plasma
The extraction procedure used in this study afforded percent-
age recovery ranges of 96–104% for linearity in the range of
50–400 ng/ml for both enantiomers, Table 3. The addition of
ammonium acetate was necessary to obtain such recoveries.Figure 4 Chromatograms of (A) blank human plasma and (B) s
haloperidol (IS) using Chirobiotic V column (mobile phase: methanol:
1 ml/min, UV detection: 315 nm).Chromatograms of a blank human plasma sample (A) and
an extracted sample from plasma (B) are in Fig. 4. It is clear
that there were no interferences from endogenous plasma con-
tents indicating the high selectivity of the proposed method.
3.4. Precision and accuracy
A summary of the accuracy and precision results in spiked hu-
man plasma is given in Table 4. The acceptance criteria (with-
in-run and between-run %RSD of less than 15% and accuracy
between 85% and 115%) were met in all cases. The within-run
precision and accuracy (n= 3) expressed as %RSD and %er-
ror were 1.9–5.5% and 2.1–3.1%, respectively, for S-(+)-aro-
tinolol and 1.9–7.1% and 2.2–3.4%, respectively, for R-()-
arotinolol.
The between-run precision and accuracy (n= 9) expressed
as %RSD and %error were 4.1–5.7% and 0.5–1.9% for S-
(+)-arotinolol, respectively, and 3.8–4.8% and 2.1–3.8% for
R-()-arotinolol, respectively.piked with (I) S-(+)-arotinolol, (II) R-()-arotinolol, and (III)
glacial acetic acid:triethylamine (100:0.020:0.030, v/v/v), ﬂow rate:
Figure 5 Chromatogram of (I) S-(+)-arotinolol (II) R-()-arotinol
Chirobiotic V column (mobile phase: methanol:glacial acetic acid:
detection: 315 nm).
Table 5 Determination of arotinolol enantiomers in pharma-
ceutical formulations by the proposed method.
Pharmaceutical
preparation
Enantiomer Nominal
conc.
(ng/ml)
Measured
conc.
(ng/ml)
Recovery
(%)
Arotinolol tableta S-(+)- 100 98.4 98.4
220 217.4 98.8
340 335.2 98.6
Overall recovery
(±SD)
98.60 ± 0.16
RSD (%) 0.16
R-()- 100 101.8 101.8
220 214.8 97.6
340 335.4 98.6
Overall recovery
(±SD)
99.30 ± 1.79
RSD (%) 1.80
a Prepared in our Labe.
Table 4 Accuracy and precision data for arotinolol enantio-
mers in spiked plasma samples.
Analyte Actual
concentration
(ng/ml)
Experimental
concentration
(ng/ml)
RSD
(%)c
Error
(%)d
Within-runa
S-(+)-arotinolol
80 82.49 ± 1.63 1.97 3.11
150 145.75 ± 8.08 5.54 2.83
300 293.53 ± 15.20 5.17 2.15
R-()-arotinolol 80 81.76 ± 1.58 1.93 2.20
150 145.61 ± 10.47 7.19 2.92
300 289.40 ± 16.73 5.77 3.46
Between-runb
S-(+)-arotinolol
80 80.71 ± 4.64 5.74 0.88
150 147.15 ± 6.06 4.11 1.90
300 298.35 ± 16.67 5.58 0.55
R-()-arotinolol 80 83.07 ± 3.98 4.79 3.83
150 146.05 ± 5.69 3.89 2.63
300 293.58 ± 14.21 4.84 2.14
a Mean ± S.D. based on n= 6.
b Mean ± S.D. based on n= 9.
c Expressed as %RSD: (S.D./mean) · 100.
d Calculated as (experimental concentration–actual concentra-
tion/actual concentration) · 100.
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The LOD and the LOQ in plasma sample as deﬁned in Section 2
were 20 and 50 ng/ml for each enantiomer, respectively (Table 3).
3.6. Application to pharmaceutical formulation
The validity of the method developed here was applied to var-
ious concentrations taken from the pharmaceutical formula-
tions for determining their content of arotinolol enantiomers.
The values of the overall drug percentage recoveries and the
%RSD value of S- and R-arotinolol enantiomers are presented
in Table 5, indicating that these values are acceptable and the
method is accurate and precise (Fig 5).
3.7. Selectivity
The analytical ﬁgures of merit for this method are shown in
Table 1. Arotinolol enantiomers were well separated under
the HPLC conditions applied. The drug was completely re-
solved from its degradation products. No interference was ob-
served in drug free human plasma samples.
Excipients commonly coformulated with the studied drug
such as magnesium stearate, cellulose, starch, calcium hydro-
gen phosphate, colloidal silicon dioxide and coloring agents,
also did not interfere with the determination of arotinolol
enantiomers, indicating the high selectivity of the method.
4. Conclusions
An enantioselective stability-indicating HPLC method was
developed for the analysis of arotinolol in standard solution.
The drug was found to degrade in alkaline, acidic, oxidative
conditions and when exposed to heat. The drug was stable to
sunlight. The method was highly selective, where degradation
products and coformulated compounds did not interfere.
The proposed method was successfully applied in human plas-
ma and in pharmaceutical preparations. It was linear over the
range of 50–400 ng/ml with a detection limit of 20 ng/ml for
each enantiomer in spiked plasma sample.
The mean RSD of the results of within-day precision and
accuracy osf the drug were 67.1%. There was no signiﬁcant
difference between inter- and intra-day studies for each enan-ol recovered from tablets spiked with (III) haloperidol (IS) using
triethylamine (100:0.020:0.030, v/v/v), ﬂow rate: 1 ml/min, UV
Chiral stability-indicating HPLC method for analysis of arotinolol 153tiomer which conﬁrmed the reproducibility of the assay. The
method was simple and suited to the routine control of the
enantiomeric excess in the bulk drug.Acknowledgements
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